High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
883.05M
+80.54%
2.950
+556.02%
960.55M
+62.87%
3.511
+152.21%
1.05B
+38.78%
4.190
+465.39%
Estimates Revision
The market is revising Upward the revenue expectations for argenx SE (ARGX) for FY2025, with the revenue forecasts being adjusted by 0.07% over the past three months. During the same period, the stock price has changed by -10.82%.
Revenue Estimates for FY2025
Revise Upward
+0.07%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-7.18%
In Past 3 Month
Stock Price
Go Down
-10.82%
In Past 3 Month
20 Analyst Rating
0Wall Street analysts forecast ARGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARGX is 753.09 USD with a low forecast of 620.00 USD and a high forecast of 1065 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Buy
1 Hold
0 Sell
Strong Buy
0Current: 542.150
Low
620.00
Averages
753.09
High
1065
0Current: 542.150
Low
620.00
Averages
753.09
High
1065
Barclays
NULL -> Overweight
maintain
2025-06-04
Reason
Barclays
Price Target
2025-06-04
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Argenx to EUR 680 from EUR 650 and keeps an Overweight rating on the shares.
Wedbush
David Nierengarten
Outperform
maintain
$715
2025-06-02
Reason
Wedbush
David Nierengarten
Price Target
$715
2025-06-02
maintain
Outperform
Reason
Wedbush analyst David Nierengarten says investors reacted negatively to Argenx's Q1 earnings, but the current share price undervalues the opportunity in the "core" MG and CIDP franchises, and completely ignores the pipeline. The firm's view is that Argenx can provide market-beating growth for the rest of the decade. The shares sold off after Q1 earnings, largely due to concerns about worsening gross-to-net as the PFS format caused a shift of Medicare patients from Part B to Part D and its higher deductible. But Wedbush thinks the selloff misses the growth potential for the PFS format, as it provides a significant step-up in patient convenience. The firm has an Outperform rating on the shares with a price target of $715.
Wedbush
Outperform
initiated
$715
2025-05-28
Reason
Wedbush
Price Target
$715
2025-05-28
initiated
Outperform
Reason
Wedbush added Argenx to the firm's Best Ideas List as it believes the company is uniquely positioned to deliver sustained, market-leading growth in the autoimmune space, driven by continued expansion of Vyvgart and an emerging pipeline of assets that can sustain long-term momentum. Wedbush has an Outperform rating on the shares with a price target of $715.
Citi
Samantha Semenkow
Buy
maintain
$803
2025-05-21
Reason
Citi
Samantha Semenkow
Price Target
$803
2025-05-21
maintain
Buy
Reason
Citi analyst Samantha Semenkow believes the growth story for Argenx remains intact and that concerns surrounding a slowing Vyvgart launch are overblown. The firm sees a "meaningful buying opportunity" on expectations of continued Vyvgart growth and a favorable risk/reward for the shares into pipeline readouts. The recent prefilled syringe approval with a "best-case label" and continued expansion of the chronic inflammatory demyelinating polyneuropathy launch should drive Vyvgart momentum over the near-term, the analyst tells investors in a research note. Citi reiterates a Buy rating on Argenx with a $803 and believes the recent pullback offers an "attractive buying opportunity."
Citizens JMP
Jason Butler
Outperform
maintain
$701 -> $699
2025-05-14
Reason
Citizens JMP
Jason Butler
Price Target
$701 -> $699
2025-05-14
maintain
Outperform
Reason
Citizens JMP analyst Jason Butler lowered the firm's price target on Argenx to $699 from $701 and keeps an Outperform rating on the shares. Argenx recently reported Q1 results slightly ahead of consensus estimates, underscoring continued success for the VYVGART franchise, the analyst tells investors in a research note. The firm anticipates the pre-filled syringe launch will be a key demand driver in 2025 and beyond.
Baird
Neutral -> Outperform
upgrade
$680
2025-05-13
Reason
Baird
Price Target
$680
2025-05-13
upgrade
Neutral -> Outperform
Reason
Baird upgraded Argenx to Outperform from Neutral with an unchanged price target of $680. The firm citers valuation for the upgrade after the stock pulled back late last week due to pricing concerns related to the Medicare redesign implement this year. While the lower average revenue per patient on Vyvgart was not fully priced into the market and will continue, the drug remains well positioned for long-term volume-driven revenue growth, the analyst tells investors in a research note. As such, Baird views the recent pullback as creating a more attractive entry opportunity.
See All Ratings
Valuation Metrics
The current forward P/E ratio for argenx SE (ARGX.O) is 41.48, compared to its 5-year average forward P/E of -78.93. For a more detailed relative valuation and DCF analysis to assess argenx SE 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-78.93
Current PE
41.48
Overvalued PE
135.76
Undervalued PE
-293.62
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-13.67
Current EV/EBITDA
31.43
Overvalued EV/EBITDA
87.21
Undervalued EV/EBITDA
-114.56
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
37.30
Current PS
9.06
Overvalued PS
68.37
Undervalued PS
6.22
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ARGX News & Events
Events Timeline
(ET)
2025-06-20
13:17:10
Halozyme says Argenx received EU approval for Vyvgart with Enhanze for CIDP
2025-06-20
13:02:30
Argenx announces European Commission approval of VYVGART subcutaneous injection
2025-06-10 (ET)
2025-06-10
18:11:18
Argenx presents new Efgartigimod data at EULAR 2025
Sign Up For More Events
Sign Up For More Events
News
Preview
9.0
06-20SeekingAlphaargenx gets EU nod for Vyvgart subcutaneous injection
Preview
9.0
06-11Newsfilterargenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease
Preview
4.0
06-10BenzingaHC Wainwright & Co. Reiterates Buy on argenx, Maintains $720 Price Target
Sign Up For More News
People Also Watch
FAQ
What is argenx SE (ARGX) stock price today?
What is argenx SE (ARGX)'s business?
What is the price predicton of ARGX Stock?
What is argenx SE (ARGX)'s revenue for the last quarter?
What is argenx SE (ARGX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for argenx SE (ARGX)'s fundamentals?
How many employees does argenx SE (ARGX). have?